Submitted by Anonymous (not verified) on 14 August 2023 - 15:30
Human medicines European public assessment report (EPAR): Mayzent, siponimod, Multiple Sclerosis, Relapsing-Remitting, Date of authorisation: 13/01/2020, Revision: 10, Status: Authorised
Source: